NewAmsterdam Pharma (NASDAQ:NAMS) & Pyxis Oncology (NASDAQ:PYXS) Head to Head Contrast

NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) and Pyxis Oncology (NASDAQ:PYXSGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares NewAmsterdam Pharma and Pyxis Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma N/A N/A N/A
Pyxis Oncology N/A -52.60% -41.08%

Institutional & Insider Ownership

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 2.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 8.4% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares NewAmsterdam Pharma and Pyxis Oncology’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NewAmsterdam Pharma $14.09 million 140.08 -$176.94 million N/A N/A
Pyxis Oncology N/A N/A -$73.79 million ($1.84) -3.03

Pyxis Oncology has lower revenue, but higher earnings than NewAmsterdam Pharma.

Risk & Volatility

NewAmsterdam Pharma has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for NewAmsterdam Pharma and Pyxis Oncology, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma 0 0 5 0 3.00
Pyxis Oncology 0 0 7 0 3.00

NewAmsterdam Pharma currently has a consensus price target of $33.25, indicating a potential upside of 50.38%. Pyxis Oncology has a consensus price target of $8.50, indicating a potential upside of 52.60%. Given Pyxis Oncology’s higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than NewAmsterdam Pharma.

Summary

Pyxis Oncology beats NewAmsterdam Pharma on 5 of the 9 factors compared between the two stocks.

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

About Pyxis Oncology

(Get Free Report)

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.